A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of SYR110322 (SYR-322) When Used in Combination With Metformin in Subjects With Type 2 Diabetes.
Latest Information Update: 28 Dec 2021
Price :
$35 *
At a glance
- Drugs Alogliptin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Sponsors Takeda; Takeda Europe Research & Development Centre
- 07 Jul 2009 Actual initiation date changed from Feb 2006 to Mar 2006 as reported by ClinicalTrials.gov.
- 07 Jul 2009 Actual end date changed from Jan 2007 to Jun 2007 as reported by ClinicalTrials.gov.
- 01 Jan 2009 Results published in International Journal of Clinical Practice.